2024 (3 POSTS)
Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693 , ISPOR Europe 2024, November 2024.
View Abstract
Publication: Abstracts and Presentations
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain, ISPOR Europe 2024, November 2024.
Publication: Abstracts and Presentations
Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I , et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045 .
View Abstract
Publication: Manuscripts
2023 (4 POSTS)
Bean K, Miller B, Jensen I , Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547 , ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Miller B, Jensen I , Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285 , ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Olaye A, Miller B, Jensen I , Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408 , ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258 .
Publication: Abstracts and Presentations
2022 (1 POST)
Pang F, Dean R, Jensen I , Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24 , ISPOR 2022.
View Abstract